CN115698303A - 体外转录物mrna和包含其的药物组合物 - Google Patents
体外转录物mrna和包含其的药物组合物 Download PDFInfo
- Publication number
- CN115698303A CN115698303A CN202180022541.2A CN202180022541A CN115698303A CN 115698303 A CN115698303 A CN 115698303A CN 202180022541 A CN202180022541 A CN 202180022541A CN 115698303 A CN115698303 A CN 115698303A
- Authority
- CN
- China
- Prior art keywords
- vitro transcript
- mrna
- tail
- transcript mrna
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 122
- 238000000338 in vitro Methods 0.000 title claims abstract description 110
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 107
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 37
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 108020004414 DNA Proteins 0.000 claims description 55
- 108091036407 Polyadenylation Proteins 0.000 claims description 43
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 238000013518 transcription Methods 0.000 claims description 31
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 27
- 230000035897 transcription Effects 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 229930024421 Adenine Natural products 0.000 claims description 13
- 101000956368 Trittame loki CRISP/Allergen/PR-1 Proteins 0.000 claims description 13
- 229960000643 adenine Drugs 0.000 claims description 13
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 241000180579 Arca Species 0.000 claims description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 50
- 210000004102 animal cell Anatomy 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000014616 translation Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000011259 mixed solution Substances 0.000 description 9
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 108091006047 fluorescent proteins Proteins 0.000 description 7
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000012858 Eukaryotic Initiation Factor-4G Human genes 0.000 description 4
- 108010057192 Eukaryotic Initiation Factor-4G Proteins 0.000 description 4
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 4
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 4
- 241000227653 Lycopersicon Species 0.000 description 4
- 240000003768 Solanum lycopersicum Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001124 posttranscriptional effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100026090 Polyadenylate-binding protein 1 Human genes 0.000 description 3
- 101710103012 Polyadenylate-binding protein, cytoplasmic and nuclear Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229940022005 RNA vaccine Drugs 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 231100000722 genetic damage Toxicity 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108091005434 innate immune receptors Proteins 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 102000028499 poly(A) binding Human genes 0.000 description 2
- 108091023021 poly(A) binding Proteins 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101800001779 2'-O-methyltransferase Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000735431 Homo sapiens Terminal nucleotidyltransferase 4A Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100034939 Terminal nucleotidyltransferase 4A Human genes 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- YIJVOACVHQZMKI-JXOAFFINSA-N [[(2r,3s,4r,5r)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 YIJVOACVHQZMKI-JXOAFFINSA-N 0.000 description 1
- OLRONOIBERDKRE-XUTVFYLZSA-N [[(2r,3s,4r,5s)-3,4-dihydroxy-5-(1-methyl-2,4-dioxopyrimidin-5-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 OLRONOIBERDKRE-XUTVFYLZSA-N 0.000 description 1
- VEWJOCYCKIZKKV-GBNDHIKLSA-N [[(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1C1=CNC(=O)NC1=O VEWJOCYCKIZKKV-GBNDHIKLSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
线性化模板DNA | 1μL |
T7酶混合物 | 2μL |
10X T7反应缓冲液 | 2μL |
T7 2X NTP/ARCA | 10μL |
无核酸酶水 | 高达20μL |
线性化模板DNA | 1μg |
T7酶混合物 | 2μL |
10X反应缓冲液 | 2μL |
酶混合物 | 2μL |
75mM ATP溶液 | 2μL |
75mM CTP溶液 | 2μL |
75mM GTP溶液 | 2μL |
75mM UTP溶液 | 10μL |
无核酸酶水 | 高达20μL |
10X ScriptCap封帽缓冲液 | 10μL |
10mM GTP | 10μL |
2mM SAM | 5μL |
ScriptGuard RNase抑制剂 | 2.5μL |
ScriptCap封帽酶(10U/mL) | 4μL |
总体积 | 31.5μL |
10X ScriptCap封帽缓冲液 | 10μL |
10mM GTP | 10μL |
20mM SAM | 2.5μL |
ScriptGuard RNase抑制剂 | 2.5μL |
ScriptCap 2’-O-甲基转移酶(100U/mL) | 4μL |
ScriptCap封帽酶(10U/mL) | 4μL |
总体积 | 33μL |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0032466 | 2020-03-17 | ||
KR1020200032466A KR102462990B1 (ko) | 2020-03-17 | 2020-03-17 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
PCT/KR2021/003281 WO2021187883A1 (ko) | 2020-03-17 | 2021-03-17 | 인비트로 트랜스크립트 mrna 및 이를 함유하는 약학조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115698303A true CN115698303A (zh) | 2023-02-03 |
Family
ID=77771801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180022541.2A Pending CN115698303A (zh) | 2020-03-17 | 2021-03-17 | 体外转录物mrna和包含其的药物组合物 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4123029A4 (zh) |
JP (1) | JP2023518734A (zh) |
KR (1) | KR102462990B1 (zh) |
CN (1) | CN115698303A (zh) |
AU (1) | AU2021239762A1 (zh) |
BR (1) | BR112022018376A2 (zh) |
MX (1) | MX2022011487A (zh) |
WO (1) | WO2021187883A1 (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
WO2013151666A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
JP6144355B2 (ja) * | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2016005004A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
KR20200103750A (ko) * | 2017-12-21 | 2020-09-02 | 바제클리크 게엠베하 | 클릭-변형된 mRNA |
-
2020
- 2020-03-17 KR KR1020200032466A patent/KR102462990B1/ko active IP Right Grant
-
2021
- 2021-03-17 MX MX2022011487A patent/MX2022011487A/es unknown
- 2021-03-17 EP EP21771925.1A patent/EP4123029A4/en active Pending
- 2021-03-17 BR BR112022018376A patent/BR112022018376A2/pt unknown
- 2021-03-17 WO PCT/KR2021/003281 patent/WO2021187883A1/ko unknown
- 2021-03-17 AU AU2021239762A patent/AU2021239762A1/en active Pending
- 2021-03-17 CN CN202180022541.2A patent/CN115698303A/zh active Pending
- 2021-03-17 JP JP2022555835A patent/JP2023518734A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4123029A1 (en) | 2023-01-25 |
AU2021239762A1 (en) | 2022-10-06 |
WO2021187883A1 (ko) | 2021-09-23 |
BR112022018376A2 (pt) | 2022-11-08 |
KR102462990B1 (ko) | 2022-11-07 |
KR20210115958A (ko) | 2021-09-27 |
JP2023518734A (ja) | 2023-05-08 |
MX2022011487A (es) | 2023-01-05 |
EP4123029A4 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230250439A1 (en) | Polynucleotide secondary structure | |
US9528137B2 (en) | Methods for cell-free protein synthesis | |
US20150344909A1 (en) | Vectors And Methods For Genetic Immunization | |
CN107208096A (zh) | 基于crispr的组合物和使用方法 | |
EP3946466A2 (en) | Compositions comprising modified circular polyribonucleotides and uses thereof | |
JP2013520158A (ja) | タンパク質生産の増強のためのmRNAの一次構造の再操作 | |
EP3684934B1 (en) | In vivo rna or protein expression using double-stranded concatemeric dna including phosphorothioated nucleotides | |
EP2307575B1 (en) | Unprocessed rolling circle amplification product | |
CN110760511A (zh) | 一种用于治疗杜氏肌营养不良症的gRNA、表达载体、CRISPR-Cas9系统 | |
US20220243243A1 (en) | Expression of products from nucleic acid concatemers | |
CN115698303A (zh) | 体外转录物mrna和包含其的药物组合物 | |
US20240226258A1 (en) | In-vitro transcript mrna and pharmaceutical composition comprising same | |
WO2022120936A1 (zh) | 一种修饰的核酸及其应用 | |
CN114107303A (zh) | sgRNA、质粒、IRF7功能缺失的细胞系及其构建方法和应用 | |
CN112266912A (zh) | 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用 | |
CN109880835B (zh) | 重组h9n2禽流感病毒株、其制备方法、禽流感疫苗及其应用 | |
CN112553200A (zh) | 一种用于敲除猪ugt2c1基因的打靶载体制备方法及其应用 | |
US20240043835A1 (en) | Systems and Methods for Enhancing Gene Expression | |
US20240002864A1 (en) | Systems and Methods for Enhancing Gene Expression | |
KR102129584B1 (ko) | 목적 유전자를 선형 벡터에 삽입하는 방법 | |
RU2804421C1 (ru) | Регуляторная последовательность для увеличения экспрессии генов | |
CN117965624A (zh) | 一种用于编码耐甲氧西林金黄色葡萄球菌内溶素的线性dna、线性rna及其质粒表达载体 | |
CN117224683A (zh) | Trim25基因作为靶点在抑制h9n2流感病毒复制中的应用 | |
CN118291452A (zh) | 一种基于i型内含子核酶体外制备环状rna的系统及其应用 | |
CN117660526A (zh) | 一种SARS-CoV-2的免疫原及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Seoul, South Kerean Applicant after: ABION Inc. Applicant after: SNU R&DB FOUNDATION Address before: Seoul, South Kerean Applicant before: ABION Inc. Applicant before: SNU R&DB FOUNDATION |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Yingji Inventor after: Cui Junying Inventor after: Jin Narong Inventor after: Sun Yuanluo Inventor after: Li Rongchen Inventor before: Shen Yingji Inventor before: Cui Junying Inventor before: Jin Naying Inventor before: Sun Yuanle Inventor before: Li Yongjin |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40084087 Country of ref document: HK |